Homocystein serum levels and lipid parameters in children with atherosclerosis risk factors;Homocysteina i wybrane parametry przemiany lipidowej u dzieci z czynnikami ryzyka miażdżycy tȩtnic

Polski Merkuriusz Lekarski

Volumn 22, Issue 128, 2007, Pages 146-149

  Sierakowska FijaŁek, Anna ^a   Kaczmarek, Piotr ^a   Pokoca, Lech ^a   Smora̧g, Ireneusz ^a   Wosik Erenbek, Marzenna ^a   Baj, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Atherosclerosis; Children; Homocystein; Lipid levels

Indexed keywords

BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ARTICLE; ATHEROSCLEROSIS; BLOOD; BODY MASS; COMORBIDITY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; OBESITY; RISK FACTOR;

ADOLESCENT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COMORBIDITY; FEMALE; HOMOCYSTEINE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID METABOLISM DISORDERS; LIPOPROTEINS; MALE; OBESITY; RISK FACTORS; TRIGLYCERIDES;

EID: 33947104720     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bailey L.B., Gregory J.F.: Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J. Nutr., 1999, 129, 919-22.
2. Berenson G.S.: Childhood risk factors predict adult risk associated with subclinical cardiovascular disease. The Bogalusa Heart Study. A. J. Cardiol., 2002, 21, 90, 3L-7L.
3. Binder C.J., Chang M.K., Shaw P.X. i wsp.: Innate and acquired immunity in atherogenesis. Nature Medicine, 2002, 11, 1218-26
4. Bailey L.B., Gregory J.F.: Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J. Nutr., 1999, 129, 919-22.
5. Chen P., Poddar R., Tipa E.V. i wsp.: Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv. Enzyme Regul., 1999, 39, 93-109.
6. Cichocka A., Cybulska B.: Homocysteina - mniej poznany czynnik ryzyka chorób sercowo-naczyniowych. Med. Metab., 1999, 2, 42-51.
7. Coronary Heart Disease: Reducing the Risk. The scientific background for primary and secondary prevention of coronary heart disease. The International Task Force for Prevention of Coronary Heart Disease in cooperation with International Atherosclerosis Society. Nutr. Metab. Cardiovasc. Dis., 1998, 8, 205-71.
8. Franescini G.: Epidemiologic evidence for high-densitylipiprotein cholesterol as a risk factor for coronary artery disease, Am. J. Cardiol., 2001, 20, 9.
9. Gaciong Z.: Nadciśnienie tȩtnicze, hiperhomocysteinemia i kwas foliowy. Czynniki Ryzyka, 2005, supl. 11, 11.
10. Hyanek J., Stribrny P., Klika M. i wsp.: Diagnostic significance of mild hyperhomocysteinemia in a population of children with parents or grandaparents who have peripheral or coronary artery disease. Cas. Lek. Cesk., 1999, 24, 138 (11), 333-36.
11. Jakubowski H.: Protein N-homocysteinylation: implications for atherosclerosis., Biomed. Pharmacother., 2001, 55, 443-47.
12. Laraqui A., Bennouar N., Meggough F. i wsp.: Homocysteine, lipoprotin (a): risk factors for coronary heart disease. Ann. Biol. Clin., 2002, 60, 5, 549-57.
13. Mahoney L.T., Burns T.L., Stanford W. i wsp.: Coronary risk factors measured in children and childhood and young adult life are associated with coronary artery calcification in young adults: the Muscatine Study. J. Am. Coll. Cardiol., 1996, 27, 277.
14. McCully K.: Vascular pathology of homocysteinemia: implication for pathogenesis of atherosclerosis. Am. J. Pathol.,1969, 56, 111-28.
15. Mc. Gill H. Jr., Mc. Mahan A., Herderich E. i wsp.: Origin of atherosclerosis in childhood and adolescence. Am. J. of Clin. Nutr., 2000, 72, 5, 1307-15.
16. Medina M., Urdiales J.L., Amores-Sanchez M.L.: Rotes of homocysteine in cells metabolism: old and new functions. Eur. J. Biochem., 2001, 268, 3871-82.
17. Nowicka G.: Badania laboratoryjne w ocenie ryzyka chorób układu kra̧żenia. w: Kardiologia zapobiegawcza. Naruszewicz M (red.), Verso s.c., 2003, 37-45.
18. National Cholesterol Education Programme. Raport of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics, 1992, 89 (supl), 525-84.
19. Scott C.H., Sutton M.S.: Homocysteine; evidence for causal relationship with cardiovascular disease. Cardiol. Rev., 1999, 7, 101-107.
20. Szymczak E., Chełchowska M., Radomyska B. i wsp.: Homocysteina i wybrane parametry przemian lipidowych u dzieci z hipercholesterolemia̧ . Med. Wieku Rozw., 2001, 5, 2, 157-64.
21. Tsai J.T., Wang H., Perrella M. i wsp.: Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J. Clin. Invest., 1996, 97, 146-53.
22. Tuck M. L.: Obesity the sympathetic nervous system and essential hypertension. J. Hypert., 1992, 19, 167.
23. Williams C.L., Hayman L.L., Daniels S.R. i wsp.: Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation, 2002, 106-43.
24. Włodarska M., Gawor Z., Piotrowski G. i wsp.: Ocena czynników ryzyka choroby niedokrwiennej serca u studentów Politechniki Czȩstochowskiej z otyłościa̧ i nadwaga̧. Czynniki Ryzyka, 2004, 1-2, 23-31.